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Constipation is a commonly encountered symptom in 
clinical practice, but uncertainty exists also the precise 
definition of the term, which has led to controversy 
concerning its incidence, pathogenesis and treatment. 
Constipation   can   be   a   result   of    primary   motor 
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disorders, other diseases, adverse effects of many 
drugs, chronic illnesses that lead to physical and 
mental impairment. However elderly women use 
laxatives more often and constipation is common in 
persons 65years and older. This may be because the 
elderly people often define constipation as need for 
strain to defecate rather than infrequency of bowel 
movements. 
Most constipated patients have no obvious cause for 
their symptoms but are presumed to have an 
underlying disorder of colonic or ano-rectal motor 
function. The most common endocrine disorders that 
cause constipation are diabetes mellitus and 
hypothyroidism. Neurological diseases are associated 
with constipation because the colonic motor functions 
are co-ordinated by extrinsic sympathetic and 
parasympathetic nerves. 
A B S T R A C T  
Context: Functional constipation which has no underlying organic causes is difficult to be allopathic 
treatment for long term due to its side effects and undeniable effect, thus a natural balanced and compatible 
formulation needs to be validated. Objectives: Current study aimed to assess a poly-herbal formulation in 
management of functional constipation. Material and Methods: This study was 28 days, two armed, 
randomized, open labeled, prospective clinical study. 60 clinically confirmed cases of functional constipation 
patients randomized to receive orally either 2 teaspoonful of PP/JLN/107/09-10 Syrup or 1 teaspoonful of 5-
6 gm of Isabgol powder. Results were analyzed as per Rome II criteria and other associated symptoms like 
headache, acidity, belching, barborgysmy, flatulence and abdominal distension or bloating which are 
recorded on VAS score. Results: PP/JLN/107/09-10 scored over Isabgol on four out of six parameters of 
Rome II Criteria viz., frequency of bowel movement, straining at defecation, lumpy I hardstool formation, 
feeling of incomplete evacuation, feeling of ano-rectal blockage and manual maneuvers (p < 0.001). Trial 
drugs showed comparable effects (p > 0.05) in reducing the mean scores of associated symptoms like 
headache, acidity, belching, borgorgysmy, flatulence and abdominal distension. However, trial drug was 
found to perform statistically significant result in more number of parameters in comparison to Isabgol. 
Conclusion: PP/JLN/107/09-10 was found to be effective and safe in reliving functional constipation.  
Key words: Functional Constipation, PP/JLN/107/09-10, Isabgol, Clinical Study, Rome II Criteria. 
Trial Registration: Clinical Trail Registry of India vides Ref. CTRI/2018/02/012110 Dated 23/02/2018. 
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Constipation is defined as having a bowel movement 
fewer than three times per week. With constipation 
stools are usually hard, dry, small in size, and difficult 
to eliminate. Constipation is a symptom, not a 
disease. Almost everyone experiences constipation at 
some point in their life, and a poor diet typically is the 
cause.  
Universally constipation (functional constipation) has 
about 10-12% incidence rate. All forms of constipation 
together account for >20% incidence. 
Constipation is one of the most common prevalent 
gastrointestinal symptoms, affecting approx. 14% of 
the population. There is no single definition of 
constipation and it can be defined by one or more 
symptoms: hard stool, infrequent stools (typically 
fewer than three per week), a sense of incomplete 
bowel evacuation, and excessive time spent on the 
toilet or in unsuccessful defecation. 
Causes 
Constipation is frequently multifactorial and can result 
from systemic or neurologic disorders or medications. 
Constipation may also be caused by conditions such 
as: Primary diseases of the colon (stricture, cancer, 
anal fissure, and proctitis) metabolic disturbances 
(hypercalcemia, hypothyroidism, and diabetes 
mellitus) Neurologic disorders (Parkinsonism, spinal 
cord lesions). 
Management 
The life style change and dietary modifications are 
helpful for the relief of mild to moderate constipation. 
Patients whose constipation is not relieved by lifestyle 
and diet change may benefit from judicious use of a 
laxative. Various classes of laxative drugs such as 
stimulant, saline, osmotic and bulk are used 
depending upon the chronicity and severity of the 
condition. Other treatment procedures such as 
enemas, suppositories, behavioural therapy and 
surgery also have a place in the management of 
constipation. 
Pelvic Floor Retralning 
Many constipated patients have pelvic function 
disorder. Surgical removal of the colon may not 
benefit patients with pelvic floor disorder. 
Behaviour and Pain Management 
Many patients with colonic dysmotility benefit from 
evaluation and therapy for stress and other 
psychosocial factors and for problems of chronic 
abdominal pain. 
Surgery Subtotal Colectomy (also called Total 
Abdominal Colectomy). 
The surgeon removes the colon then joins the end of 
the small bowel to the top of the rectum. The Surgery 
does not cause loss of stool control because the anal 
sphincter remains intact. Following surgery, patients 
can expect to have from one to four bowel 
movements each day. 
The procedure can be performed by open or 
laparoscopic surgery. The stimulant laxatives, osmotic 
and saline laxative are reported to cause abdominal 
cramping, hypokalemia, flatulence, abdominal 
distension and alters electrolyte transportation etc. 
which limits their use on long-term. 
There are several laxative as well as purgative agents 
described under various categories. The main 
categories are: Virechana/purgatives Ex. Danti 
(Baleospermum montanum), Sramsana/laxatives Ex. 
Aragvadha (Cassia fistula), Bhedana/cholertics Ex. 
Katuki (Picrorrhiza kurroa), Mrudurechana/mild 
laxatives Ex. Trivrit (Operculina turpethum), 
Tivrarechana/ cathartics Ex. Eranda (Ricinus 
communis) and Virechanopaga /pro-drugs to 
purgatives Ex. Yashtimadhu (Giycyrrhiza glabra).  
The ingredients of the formulation are known for their 
inherent traditional pharmaco-therapeutic effects on 
bowel regulation. Therefore the present study is 
planned to evaluate the efficacy of the 
JLN/PP/107/09-10 in comparison with marketed 
herbal laxative formulations like lsabgol etc. 
OBJECTIVES OF THE STUDY 
The study objectives were to evaluate the efficacy 
JLNIPP/107 syrup in the management of functional 
Constipation and to compare the efficacy of 
JLN/PP/107 with Isabgol powder in the management 
of functional Constipation. 
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METHODOLOGY 
This was an Open label, Comparative, Prospective, 
Randomized trial. A randomization chart given by the 
bio-statistician is followed to remove any bias in the 
enrolment of subjects. About 60 clinically confirmed 
Functional Constipation subjects between the age 
group of 20 -60 years belonging to both the sex were 
randomized and allocated into two groups viz., Group 
A and Group B wherein Group A is administered with 
the trial drug while Group B received the Isabgol 
powder. 
Study Participants 
Subjects presenting with either or all symptoms as 
mentioned in the inclusion criteria were provisionally 
included in the study from the outpatient department 
of Kayachikitsa (Internal Medicine), S.J.S. Ayurvedic 
College & Hospital, Nazratpettai, Chennai. 
Subject selection Criteria 
Subjects presenting with two or more of the following 
for at least 12 weeks (not necessarily consecutive) in 
the preceding 12 months. (The Rome II criteria) viz., 
Straining during > 25% of bowel movements, Lumpy 
or hard stools for> 25% of bowel movements, 
Sensation of incomplete evacuation for > 25% of 
bowel movements, Sensation of anorectal blockage 
for> 25% of bowel movements, Manual manoeuvres 
to facilitate> 25% of bowel movements (e.g. digital 
evacuation or support of the pelvic floor) and Less 
than 3 bowel movements per week were included in 
the study. Only the subjects in the age group 18-60 
years who are willing to sign informed consent and to 
come for regular follow- up examinations as & when 
required were included. 
Patients with diagnosed colonic inertia, anorectal 
surgery, structural abnormalities, like: rectal prolapse, 
rectocele, rectal intussuception, anorectal stricture, 
solitary rectal ulcer syndrome 
Perineal descent, Colonic I rectal mass or tumor with 
obstruction e.g. adenocarcinoma, Colonic stricture: 
radiation, ischemia, diverticulosis, Hirschsprung's 
disease,Idiopathic megarectum, Intestinal obstruction 
were excluded. Patients with diagnosed neurological 
problems, Patients with serious systemic ailments, 
Pregnant or lactating females and those patients on 
chronic medication (>60 days) and/or who are on 
medications known to cause constipation were also 
excluded. 
Study End Points 
2 weeks of intervention with JLN/PP/107 Syrup in 
Group A and Isabgol powder in Group B was taken as 
therapeutic end point.  Any improvement or relief 
from clinical symptoms related to constipation at the 
end of 2 weeks and 4 weeks or by the resolution of 
symptoms whichever stands early and the Clinical 
Global Response by Physician were considered as 
clinical end points.  
Study interventions 
PP/JLN/107/2009-10 has Trivrit (Operculina 
turpethum) 300 mg Yashtimadhu (Glycyrrhiza glabra) 
75 mg with excipients qs. Subjects in group A were 
advised to take PP/JLN/107/2009-10 in a dose of 2 
Teaspoonful (10ml) at Bed time and in Group B to 
take Isabgol powder, (5-6g) one teaspoonful at Bed 
time. 
Study Procedure 
Study period of 2 weeks with weekly follow up and a 
post treatment follow up for another 2 weeks after 
the therapy was planned. There were three visits 
apart from the baseline visit. Improvement in 
constipation on a Clinical Scoring system as per the 
Rome II criteria. Frequency of bowel movement (0 to 
2 point scale), Straining at defecation (VAS scale), 
Lumpy or hard stools (VAS scale), Sensation of 
incomplete evacuation (VAS scale), Sensation of ano-
rectal blockage (VAS scale), Manual maneuvers 
required per week (0 to 2 point scale where 2 is more 
than two manual maneuvers required per week while 
score of 1 is considered as 1 to 2 manual maneuvers 
per week. Score of 0 indicates subjects without 
manual manoeuvres) along with symptoms like 
headache, acidity, belching, borborgysmy, flatulence 
and abdominal distension or bloating are recorded on 
VAS scale. 
VAS was taken as 0 to 33 considered free from 
symptoms or negligible symptoms of constipation. 
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Scores from 34 to 67 is moderate constipation while 
68 to 100 is severe constipation. 
Complete Blood profile, Liver Function Test (SGOT, S. 
Bilirubin), Renal function Tests (B. urea, S. creatinine), 
Urine Analysis (R, M) were also carried out for safety 
assessment. USG of abdomen was also carried out 
while screening to rule out any structural anomalies.  
Fig. 1: Patient enrollment flow chart: CONSORT 2010 
flow diagram 
 
OBSERVATIONS AND RESULTS 
Total 60 subjects falling under the inclusion criteria 
were recruited and randomised equally to group A 
and group B. Among them, all were clinically 
confirmed Functional Constipation subjects, belonging 
to the age group of 20- 60 years. Demographic details 
are given in Table 1. 
Table 1: Demographic details 
Group Male Female Mean Age in 
yrs 
A (n=30) 10 20 37.67±18.10 
B (n=30) 11 19 42.37±14.35 
Effect on frequency of bowel movement 
In group A, the mean score on Rome II Scale was 1.48 
(out of 2 points) at the baseline which was reduced to 
1.26 and 1.11 at the end of visit 1 and visit 2 
respectively. The reduction was statistically significant 
(p < 0.05). The score was further reduced to 1.07 at 
the end of visit 3. In group B, the mean score on Rome 
II Scale was 1.33 (out of 2 points) at the baseline 
which was reducedto1.10 and 1.03 at the end of visit 
1 and visit 2 respectively. The reduction was 
significant (p < 0.05.) The score was slightly increased 
to 1.13 at the end of visit 3. 
Effect on Straining at Defecation 
The baseline mean score was 85.33 while it was 13.33 
after visit 2. The reduction was statistically highly 
significant p < 0.001. The score was decreased to 8.33 
at the end of visit 3(i.e., after the follow up period of 2 
weeks without medicine. In group B, The baseline 
mean score was 79.00 while it was 25.33 after visit 2. 
The reduction was statistically highly significant p < 
0.001. The score was increased to 27.67 at the end of 
visit 3 (i.e., after the follow up period of 2 weeks 
without medicine). 
Effect on Lumpy or Hard stools 
The baseline mean score was 84.67 while it was 8.33 
after visit 2. The reduction was statistically highly 
significant p < 0.001. The score was increased to 10.33 
at the end of visit 3. In group B, the baseline mean 
score was 74.67 while it was 26.33 after visit 2. The 
reduction was statistically highly significant p < 0.001. 
The score was increased to 27.67 at the end of visit 3.  
Effect on Feeling of Incomplete Evacuation 
The baseline mean score was 81.00 while it was 15.67 
after visit 2. The reduction was statistically highly 
significant p < 0.001. The score was increased to 14.00 
at the end of visit 3 (i.e., after the follow up" period of 
2 weeks without medicine).The baseline mean score 
was 72.67 while it was 25.67 after visit 2. This 
reduction was statistically significant (p<0.001). The 
reduction was statistically highly significant p < 0.001. 
The score was increased t(l 27.33 at the end of visit 3.  
Effect on Feeling of Anorectal Blockage 
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The baseline mean score was 57.59 while it was 12.07 
after visit 2. The reduction was statistically non-
significant (p>0.05). The score was increased to 12.76 
at the end of visit 3 (i.e., after the follow up period of 
2 weeks without medicine).The baseline mean score 
was 47.00 while it was 24.67 after visit 2. This 
reduction was statistically non-significant (p>0.05). 
The score was almost the same (24.33) at the end of 
visit 3. 
Effect on Manual Maneuvers 
It is observed that 13 subjects out of 30 subjects in 
group A have reported with requirement of some 
manual maneuver for defecation at the base line. 
There were 1 subject, 9 subjects and 3 subjects 
respectively in the score range of 2, 1 and 0 in group A 
These were observed to be 0 subjects, 5 subject and 8 
subjects respectively at visit 1;1 subject, 3 subject and 
9 subjects respectively at visit 2; and 2 subjects, 6 
subject and 5subjects respectively at visit 3. In group 
B, there were 1 subject, 7 subjects and 2 subjects 
respectively in the score range of 2, 1 and 0 at 
baseline. These were observed to be 1 subject, 4 
subject and 4 subjects respectively at visit 1; 1 subject, 
4 subject and 4 subjects respectively at visit 2; and 1 
subjects, 6 subject and 2 subjects respectively at visit 
3. 
PP/JLN/107/09-10 scored over Isabgol on four out of 
six parameters of Rome II Criteria viz., frequency of 
bowel movement, straining at defecation, lumpy I 
hardstool formation, feeling of incomplete 
evacuation, feeling of ano-rectal blockage and manual 
maneuvers (p < 0.001).Trial drugs showed comparable 
effects (p > 0.05) in reducing the mean scores of 
associated symptoms like headache, acidity, belching, 
borgorgysmy, flatulence and abdominal distension. 
However, their inter-group mean score reduction on 
respective symptoms are statistically significant 
(p<0.05). 
It is noticed that subjects in group A required less 
medical administration compared to group B. This is 
proved from the fact that number of subjects who 
achieved clinical end points before completion of 2 
weeks in group Aare 11 against 02 in group B. The 
continued relief noted during follow-up period is 
more with group A when compared to group B. 
Effect of study drug on various associated parameters 
is presented in Fig 2 and 3. PP/JLN/107/09-10 showed 
clinically significant reduction in various associated 
parameters like headache, acidity, borborgymy, etc. 
Fig 2: Associated symptoms in Group A 
 
Fig 3: Associated symptoms in Group A 
 
DISCUSSION 
Constipation can be classified into three broad 
categories: normal-transit constipation, slow transit 
constipation, and disorders of defecatory or rectal 
evacuation. More than one mechanism may 
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criteria" is the widely accepted format for diagnosis of 
constipation. 
"Functional" constipation or Normal-transit 
constipation is the most common form of constipation 
in which stool traverses at a normal rate through the 
colon and the stool frequency is normal, yet with a 
subjective feeling of constipation. The patients may 
experience bloating and abdominal pain or 
discomfort, and they may exhibit increased 
psychosocial distress; some may have increased rectal 
compliance, reduced rectal sensation, or both. 
According to Ayurveda, Vibandha (constipation) may 
occur in Ama-Avastha, Vata-vriddhi, Lakshana in 
various diseases Udavarta, Pureeksha-kshya, Vata-
Vriddhi in old age etc. Patients suffering from 
constipation who are having Amalakshanas like 
Balabramsa, Gourava, Alasya, Apakti, Aruchi etc. 
should not be given laxatives. For those Deepana, 
Pachana and Amahara drugs will relieve constipation 
as well as other symptoms. 
Operculina turpethum (Linn.) is a stout twiner with 
qudrangular stem. In Vedic literature, it is quoted by 
Sounaka (Sou. 19/27/3). Though Syama is described in 
Kousikasutra (103/7), it is considered as the synonym 
of Bhringaraja or Nili. Syamaka is also found in the 
Vedic literature. Acharya Caraka emphasized Trivrit as 
the best herbs for 'Sukhavirecana' (laxative). He 
described elaborately the different formulation of 
Trivrit for Virecana (purgation) in one chapter in 
Kalpasthana entitled 'SyamaTrivritKalpam'. He further 
explained that it is of two kind’s viz., Aruna and 
Syama. The second variety is considered to relieve 
even severe constipation. Bhavamisra while quoting 
two varieties of Trivrit (Sveta and Syama), explained 
that both are drastic purgatives but the black variety 
is inferior variety. In the market we come across the 
samples of Marsedenia tenasissima root being sold as 
Trivrit. Trivrit is indicated in Sotha, Udara, Arsas, 
Pandu, Kamala, Jvara, Vibandha, Pliharoga, Krimi. 
Trivrit Root I Root bark is used in Ayurvedic practice 
for Vatarakta (B.P. & V.S.) Stanyasodhana (C.S.Ci.30, 
Vishamajvara V.M., Netraroga (S.S.Ut. 10) in a dose of 
powder 1-3 g. 
Root contains resin in varying amounts (9-10%- 
Bhattacharya, 1961; 10-12%- Prasad et al, 1961; 12-
13% Shah et al, 1961). The resin contained the 
glycosides, turpethin, a-turpetheinand 13-turpethein 
(Wealth of India, 1966). It also contained a coumarin, 
scopoletin, glucose, rhamnose and fuctose '(Shah et 
al., 1972). Turpenthinic acids A, B, C, D and E isolated 
from resin (Pianta Med. 1978, 33, 144). Betulin, lupeol 
and 13-sitosterol isolated from stem 
(ActaCienc.Indica, Chem. 1987,13, 171; Chem. Abstr. 
1989,111,36646 r). The LD50 of the 50% ethanolic 
extract of 0. turpethum (whole plantexcluding roots) 
was> 1000 mg/kg i.p. in mice (Aswal et al., 1984). The 
cathartic effect of Trivrit is reported in a clinical study 
(n=30). The root powder of O.turpethum was 
administered at a dose of 5 g with water at bed time 
(Tripathi, 1989). 
Madhuka or Madhuyashtika are known to the 
physicians, since vedic period. Atharva Parisista 
described Madhuka and is considered as 
Dourbhagyanasana and Garbhabamhana. 
Commentators like Sayana identified it with 
Yastiimadhu. It was used in the treatment of animal 
poisons (Jangamavisha). Madhuyastika is quoted in 
the context of "Mulavidhi" (Pa.Gr.1/21). Brhat Trayi 
used this herb extensively in therapeutics but Caraka 
included it in many of Hiskashayavargas. He also 
emphasized its utility among Rasayana drugs. It is 
indicated in Vranasotha, Chardi, Trshna, Visharoga, 
Kshaya, Daha, Raktapitta, Hrdroga, Vrana, Vibandha, 
Bhagandara (S.S.Ci.8), Arthavabhedaka (S.S.Ut.26) 
and Hrdroga (C.S.Ci.26). Satapakamadhukataila; 
Madhuyashtyaditaila; Yashtyadichurna etc. Important 
Preparations of Yashtimadhu. 
Glycyrrhizin (principal sweetening agent), glycyrrhizic 
acid, glycyrrhetinic acid, liquirtin, isoliquiritin, 
neoisoliquiritin, liquiritogenin, isoliquiritogenin, 
glabrine, glabranine, licuraside, licochalcones A & B, 
hispagla-bridin A & B licoricidin, glabrene, liquiritic 
acid, glabrolide etc. are some of active ingredients of 
Yashtimadhu. In vivo study onisoliquiritigenin, a 
flavonoid isolated from the roots of Glycyrrhiza 
glabra, isoliquiritigenin produced a dual dose-related 
effect on the charcoal meal travel, inhibitory at the 
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low doses, while prokinetic at the high doses. In vitro, 
isoliquiritigenin showed an atropine-sensitive 
concentration-dependent spasmogenic effect in 
isolated rat stomach fungus. However, a spasmolytic 
effect was observed in isolated rabbit jejunums, 
guinea pig ileums and atropinizedrat stomach fungus, 
either as non competitive inhibition of agonist 
concentration-response curves, inhibition of high K(+) 
(80 mM)-induced contractions, or displacement of 
Ca(2+) concentration-response curves to the right, 
indicating a calcium antagonist effect. Pretreatment 
with N (omega)-nitro-L-arginine methyl ester (L-
NAME; 30 microM), indomethacin (10 microM), 
methylene blue (10 microM), tetraethylammonium 
chloride (0.5mM), glibenclamide (1 microM), 4-
aminopyridine (0.1 mM), or clotrimazole (1 microM) 
did not inhibit the spasmolytic effect. 
These results indicate that isoliquiritigenin plays a 
dual role in regulating gastrointestinal motility, both 
spasmogenic and spasmolytic. The spasmogenic effect 
may involve the activating of muscarinic receptors, 
'while the spasmolytic effect is predominantly due to 
blockade of the calcium channels (Chen G. et al., 
2009). 
Thus, our study findings and various other research 
findings on ingredients suggest that a combination of 
Trivrit as Sukhavirechaka drug with Yashtimadhu as 
Virechanopaga drug in the management of functional 
constipation can be beneficial in terms of efficacy and 
safety.  
CONCLUSION 
From the above findings it is concluded that the trial 
drug PP/JLN/107/09-10 is both clinically and 
statistically significant (p < 0.001) compared to Isabgol 
in the management of functional constipation. The 
trial drug did not produce any side-effects. 
PP/JLN/107/09-10 exhibited clinically as well as 
statistically significant (p < 0.05) relief from 
constipation. Trial drug PP/JLN/107/09-10 syrup 
showed a better relief in subjects suffering from 
functional constipation in comparison to the Isabgol. 
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